Evaluation of Safety and Efficacy of PDP-716

Summary

The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.

Timeline

Start

2018-09-13

Primary completion

2020-12-01

Completion

2020-12-01

Outcome

Met primary endpoint

release “The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan® P 0.1% dosed 3 times a day.” sparc.life ↗

Drugs

Indications